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The replication-dependent histone mRNAs, the only eukaryotic mRNAs that do not have poly(A) tails, are
present only in S-phase cells. Coordinate posttranscriptional regulation of histone mRNAs is mediated by the
stem-loop at the 3 end of histone mRNAs. The protein that binds the 3 end of histone mRNA, stem-loop
binding protein (SLBP), is required for histone pre-mRNA processing and is involved in multiple aspects of
histone mRNA metabolism. SLBP is also regulated during the cell cycle, accumulating as cells enter S phase
and being rapidly degraded as cells exit S phase. Mutation of any residues in a TTP sequence (amino acids 60
to 62) or mutation of a consensus cyclin binding site (amino acids 99 to 104) stabilizes SLBP in G2 and mitosis.
These two threonines are phosphorylated in late S phase, as determined by mass spectrometry (MS) of purified
SLBP from late S-phase cells, triggering SLBP degradation. Cells that express a stable SLBP still degrade
histone mRNA at the end of S phase, demonstrating that degradation of SLBP is not required for histone
mRNA degradation. Nuclear extracts from G1 and G2 cells are deficient in histone pre-mRNA processing,
which is restored by addition of recombinant SLBP, indicating that SLBP is the only cell cycle-regulated factor
required for histone pre-mRNA processing.
Histone mRNAs are tightly regulated during the cell cycle,
allowing the synthesis of histone protein to occur coordinately
with the replication of DNA. The metazoan replication-depen-
dent histone mRNAs are unique in that they are the only
eukaryotic mRNAs that do not end in poly(A) tails. Instead
they end in a highly conserved 26-nucleotide sequence that
contains a stem-loop (25). The mRNAs for all five histone
proteins are coordinately regulated, and the majority of the
regulation is posttranscriptional (17). There is only a three- to
fivefold change in the rate of transcription of the histone genes
during the cell cycle (7, 18) but a 35- to 50-fold increase in the
steady-state levels of histone mRNA. The 3 end of histone
mRNAs is the cis-acting element that coordinates the post-
transcriptional regulation of the histone mRNAs (3). The ef-
ficiency of histone pre-mRNA processing is regulated as cells
progress from G1 to S phase (17, 23, 40), accounting for the
additional 10-fold increase in histone mRNA levels during S
phase. At the end of S phase, the half-life of histone mRNA
becomes very short, resulting in a rapid decrease in histone
mRNA levels (17, 44).
The only processing event required for formation of mature
histone mRNA is an endonucleolytic cleavage after the stem-
loop (13). Cleavage of the pre-mRNA requires two cis ele-
ments: the stem-loop and a purine-rich region 3 of the stem-
loop, termed the histone downstream element, that binds U7
snRNP (6, 31, 32, 39). The only protein that binds the 3 end
of histone mRNA is the stem-loop binding protein (SLBP) (24,
43). SLBP is required for histone pre-mRNA processing (10)
and remains with the mature mRNA, stimulating histone
mRNA translation (37) as part of the histone messenger RNP
(mRNP) (16), making it an ideal factor to participate in coor-
dinate regulation of histone mRNAs. We have recently shown
that SLBP is a cell cycle-regulated protein, accumulating just
prior to entry into S phase and being rapidly degraded by the
proteasome at the end of S phase, similar to the timing of
degradation of histone mRNAs (44). The translation of the
SLBP mRNA is activated as cells approach S phase, and SLBP
is rapidly degraded as cells exit S phase (44).
Here we demonstrate that a sequence in the amino-terminal
domain of SLBP is necessary for the rapid degradation of
SLBP at the end of S phase. This region contains a consensus
cyclin phosphorylation site and a consensus cyclin binding site.
Mutation of either of these sequences stabilizes SLBP. Despite
the fact that SLBP is stabilized, histone mRNA is degraded at
the appropriate time. We also show that SLBP is the only fac-
tor necessary for histone pre-mRNA processing that is missing
from either G1 or G2 cells that are continuously cycling. Thus,
SLBP is the critical factor responsible for the posttranscription-
al component of the cell cycle regulation of histone mRNA.
MATERIALS AND METHODS
Cell culture and synchronization. HeLa cells were grown in Dulbecco modi-
fied Eagle medium plus 10% fetal calf serum and penicillin-streptomycin on
10-cm-diameter plates. The cells were plated at a low density 48 h before the
double-thymidine block was initiated and were synchronized exactly as previously
described (44). After release from the block, cells were harvested at 2-h intervals,
and protein and/or RNA was prepared. An aliquot of the cells from each time
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point was taken for flow cytometry which was performed after the cells were fixed
and stained with propidium iodide as described previously (44).
Cloning of SLBP mutants. To construct pcDNA3-HA-SLBP, the NcoI frag-
ment of SLBP cDNA was ligated to pcDNA3-HA digested with HpaI. To gen-
erate pcDNA-His-SLBP or pcDNA-Myc-SLBP, the PCR fragment of the SLBP
coding region was ligated either to pcDNA-Myc (3) digested with EcoRV/XbaI
or pcDNA-His vector digested with HpaI/XbaI. To construct the expression
plasmid for the hemagglutinin (HA)-tagged SLBP deletion mutants, 54N,
124N, 13C, 52C, 72C, 65N/13C, the PCR fragments of the coding
region for these deletions were ligated to pcDNA-HA digested with HpaI and
XbaI. All of these expression plasmids were checked by restriction digestion with
appropriate enzymes and verified by DNA sequencing.
All site-directed mutations were made starting with pcDNA-His-SLBP accord-
ing to the QuickChange Site Directed Mutagenesis protocols (Stratagene) using
appropriate complementary oligonucleotides ranging from 30 to 50 nucleotides
in length. Dimethyl sulfoxide (2%) was added to all the PCR mixtures. All
mutations were verified by DNA sequencing.
Transfection and selection of stable transfectants. Transfections were done
with Lipofectamine (GibcoBRL) according to the manufacturer’s protocol. Ten
micrograms of each plasmid was used with each 10-cm-diameter plate. For
selection of stably transfected cells, 24 h after transfection, cells were replated
onto fresh plates and allowed to grow for another 24 h. Then 500 g of G418 per
ml was added to the medium. The medium containing G418 was changed every
2 days to remove dead cells. Cells were kept under selection until separate
colonies could be observed by eye on the plates, and these stably transfected cells
(at least 20 colonies per plate) were pooled together. To maintain the stably
transfected cells, 200 g of G418 per ml was kept in the medium and was
removed just prior to synchronization.
Analysis of SLBP protein and histone mRNA. Stably transfected HeLa cells
were synchronized by a double-thymidine block as previously described (44).
After release from the thymidine block, cells were collected at 2-h intervals, and
the levels of SLBP were determined by Western blotting with anti-SLBP anti-
body or anti-HA antibody for the HA-tagged deletions. Detection with the SLBP
antibody allowed the direct comparison of the levels of transfected SLBP mu-
tants and endogenous SLBP.
For analysis of histone mRNA after the cells were released from the thymidine
block, cells were collected at 2-h intervals, and total RNA was isolated using
TRIzol (GibcoBRL). An aliquot of the same cell suspension was used for anal-
ysis of SLBP. Histone mRNA levels were analyzed by Northern hybridization
using randomly labeled mouse H3.2-614 DNA as a probe.
Nuclear extract preparation and in vitro processing. An 86-nucleotide histone
pre-mRNA substrate was synthesized and labeled at the 5 end as previously
described (10). To prepare nuclear extracts from synchronized HeLa cells, HeLa
cells were split at a low density 2 days before synchronization. Cells were syn-
chronized by double-thymidine block. By the end of the synchronization process,
cells reached 80 to 90% confluence. Cells were collected 2 to 3 h after release
from thymidine block for S-phase cells, 8 to 8.5 h after release for G2-phase cells,
and 12 to 14 h after release for G1-phase cells. Twenty to forty p150 plates were
used for each cell cycle point. The nuclear extracts were prepared as previously
described (27), and assayed for SLBP by Western blotting and mobility shift
assay.
Each processing reaction was performed in a total volume of 10 l containing
5 l of the nuclear extract, 5 ng of the pre-mRNA substrate labeled at the 5 end
with [-32P]ATP, and 20 mM EDTA. Samples were incubated at 32°C for 60 min,
and the RNA was isolated by phenol extraction and analyzed as previously
described (10). A complete set of experiments was performed with extracts
prepared in parallel from cells in S, G2, or G1 phase synchronized starting from
the same initial cell culture.
Expression and purification of recombinant SLBP proteins. Recombinant
His-tagged SLBP was prepared as previously described and purified by affinity
chromatography on Ni-agarose (10).
Cell fractionation. For fractionation of cells into nuclear and cytoplasmic
fractions, nuclear extracts were prepared as described above. For fractionation of
cells into nuclear, polyribosomal, and cytosol fractions, the cells were lysed with
0.1% Nonidet P-40 (NP-40) in 0.32 M sucrose–1 mM spermidine, the nuclei were
removed by centrifugation at 1,000  g for 10 min, and polyribosomes and
cytosol were prepared as described previously (16).
Analysis of phosphorylated proteins. His-tagged SLBP was purified from
synchronous cells that had been treated with MG132 for 4 h, 4 h after release
from the double-thymidine block. Total cell extracts in 20 ml of lysis buffer (50
mM Tris-HCl [pH 7.5], 0.15 M NaCl, 50 mM NaF, 0.5% NP-40) were passed
over a Ni-agarose column, the column was washed with 10 volumes of buffer
containing 20 mM Tris-HCl (pH 8.5), 500 mM KCl, 5 mM imidazole, 10 mM
2-mercaptoethanol, and 10% glycerol, followed by 2 volumes of buffer containing
20 mM Tris-HCl (pH 8.5), 1 M KCl, 10 mM 2-mercaptoethanol, and 10%
glycerol. The bound proteins were eluted with a solution containing 100 mM
imidazole, 20 mM Tris-HCl (pH 8.5), 100 mM KCl, 10 mM 2-mercaptoethanol,
and 10% glycerol. The peak fractions were combined, EDTA was added to a
concentration of 20 mM, and then 5 g of biotinylated stem-loop RNA (synthe-
sized by Dharmacon, Boulder, Colo.) was added and incubated on ice for 2 h.
Streptavidin beads were added to bind the biotinylated RNA, washed extensively
with buffer containing 20 mM HEPES (pH 7.9), 20% glycerol, 100 mM KCl, 0.2
mM EDTA, and 0.5 mM dithiothreitol, followed by several washes with phos-
phate-buffered saline to remove all traces of glycerol. An aliquot of the beads was
analyzed by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis.
The remainder was digested with trypsin and then analyzed by mass spectrometry
(MS).
The tandem mass spectrometric analyses were performed on an ABI QSTAR-
Pulsar (QSTAR) (Applied Biosystems Division, Perkin-Elmer Corp., Foster
City, Calif.), with nitrogen as the collision gas. The QSTAR was coupled on line
to an Agilent 1100 capillary liquid chromatography (LC) system (Agilent, Palo
Alto, Calif.) equipped with an external LC Packings (San Francisco, Calif.)
splitter to produce a flow rate of 200 nl/min. The chromatography was performed
using a 75-m-diameter capillary column (PepMap C18; 3-m particle size) from
LC Packings and a water-acetonitrile gradient with both mobile phases contain-
ing 0.1% formic acid. The mobile-phase composition was held at 5% acetonitrile
for 5 min. The concentration of acetonitrile was then increased at a rate of 1%
acetonitrile per min, until 75% acetonitrile was reached. The acetonitrile con-
centration was then increased by 3% per min for 5 min to 90% acetonitrile, held
at 90% acetonitrile for 30 min, and then reduced to 5% to recondition the
column. For the diphosphorylated T13 peptide, the gradient used was different,
with the composition being held at 5% acetonitrile for the first 30 min. The
concentration of acetonitrile was then increased to 70% over 65 min (1% per
min). The acetonitrile concentration was then increased to 90% over 20 min (1%
per min) and then dropped to 5% to allow the column to reequilibrate to the
initial conditions. Liquid chromatography coupled on line to tandem MS (LC-
MS/MS) was performed by selecting a precursor ion, combined with the Pulsar
feature of the Q-STAR, to maximize both the duty cycle of the mass spectrom-
eter for the selected precursor ion and the sensitivity for any product ions formed
which are within the selected mass range, thus optimizing the mass spectrometric
sensitivity for these selected product ions. In these experiments, only the mass
spectrometric cleavage products of the m/z 560.27 ion (the m/z of the triple-
charged monophosphorylated T13 peptide) and the m/z 586.9 ion (the m/z of the
triple-charged diphosphorylated T13 peptide) were monitored. As standards, an
unphosphorylated tryptic peptide (RPESFTTPEGPKPR) corresponding to
amino acids 55 to 68 from SLBP, as well the mono- (T61) and diphosphorylated
(T60T61) peptides on the equivalent of T60 and T61 were synthesized at the
University of North Carolina Peptide Synthesis Facility.
RESULTS
A region of the amino-terminal domain of SLBP is required
for SLBP degradation at the end of S phase. To determine the
requirements for degradation of SLBP and the relationship of
SLBP degradation to histone mRNA degradation, we con-
structed several epitope-tagged mutants of SLBP and ex-
pressed them stably in HeLa cells. These cells were then syn-
chronized using a double-thymidine block, and the levels of the
mutant SLBPs were determined, using the anti-SLBP antibody
that detects both the endogenous and exogenous SLBP pro-
teins (Fig. 1). In S-phase cells, both HA-tagged and His-tagged
SLBPs were expressed at levels similar to the level of endog-
enous SLBP during S phase (Fig. 1A and B, lanes 2 to 4). The
levels of both the endogenous and tagged SLBPs rapidly de-
clined as cells exited S phase. In cells blocked at the G1/S
border, the tagged proteins accumulated to a lesser extent than
the endogenous SLBPs. There was very little HA-tagged SLBP
present in the cells blocked at the G1/S border, although levels
of HA-tagged SLBP were rapidly increased as cells were re-
leased and entered S phase (Fig. 1A, lanes 1 and 2). The low
level of HA-tagged SLBP in blocked cells is a result of the
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instability of the tagged protein, which is rapidly degraded in
cells not synthesizing DNA (unpublished results with M. L.
Whitfield). In contrast, the His-tagged protein accumulated to
significant levels in the cells blocked at the G1/S border (Fig.
1B, lane 1), as did the endogenous SLBP (44).
The expression of the exogenous SLBP resulted in at most a
two- to fourfold increase in SLBP levels, depending on the
construct, suggesting that this level of overexpression should
not overwhelm the normal cellular regulatory systems. There
was no effect on cell growth or progression through the cell
cycle in cells transfected with the full-length SLBPs. Progres-
sion through the cell cycle was monitored by flow cytometry in
all experiments, and a typical profile is shown in Fig. 1C for
cells transfected with the His-tagged SLBP.
A series of deletion mutants of SLBP with an HA tag on the
amino terminus were constructed and stably introduced into
HeLa cells. Since many of these constructs lacked the C ter-
minus of SLBP that contains the peptide antigen used for
preparation of the SLBP antibody, we used an antibody di-
rected against the HA tag to detect these proteins. Deletion of
amino acids 58 to 123 resulted in a protein that was not rapidly
degraded at the end of S phase (Fig. 1D), while deletions of
amino acids 1 to 54 (Fig. 1D) or deletion of the last 72 amino
acids had no effect on SLBP metabolism (Fig. 1D). We ana-
lyzed the region from amino acids 58 to 123 to identify the
amino acids required for SLBP degradation.
Identification of a potential phosphorylation site responsi-
ble for SLBP degradation. We previously showed that inhibi-
tion of the proteasome in late S-phase cells resulted in the
accumulation of a phosphorylated form of SLBP, suggesting
FIG. 1. Cell cycle regulation of HA-tagged and His-tagged SLBP. SLBP was cloned into the pcDNA3-HA (A) or pcDNA3-his (B) vector and
transfected into HeLa cells, and stably transfected cells were selected. The cells were synchronized by a double-thymidine block, arresting the cells
at the G1/S border (time zero [lane 1]). Cells were released from the block, and total proteins were prepared at 2-h intervals after release (times
shown above the lanes). The proteins were resolved by gel electrophoresis on an SDS–12.5% polyacrylamide gel, and the proteins were transferred
to nitrocellulose filters and assayed by Western blotting using an SLBP antibody. The positions of the HA-tagged SLBP (HA-SLBP) or His-tagged
SLBP (His-SLBP) and endogenous SLBP are indicated to the left of the gels. (C) Flow cytometry analysis of the synchronized cells in panel B.
Chromosome content is shown on the x axis, and cell number is shown on the y axis. (D) Three deletion mutants of SLBP tagged with HA at the
amino terminus and missing the first 54 amino acids (HA-54N), the last 72 amino acids (HA-72C), or amino acids 57 to 121 and the last 13
amino acids (HA-65N-13C) were transfected into HeLa cells, and stably transfected cells were selected. The cells were synchronized by a
double-thymidine block, arresting the cells at the G1/S border (time zero [lane 1]). Cells were released from the block, and total proteins were
prepared at 2-h intervals after release (times shown above the lanes). The proteins were resolved by gel electrophoresis on an SDS–12.5%
polyacrylamide gel, transferred to nitrocellulose filters, and assayed by Western blotting using an anti-HA antibody. WT, wild type; N-ter and C-ter,
N- and C-terminal regions, respectively; RBD, RNA binding domain.
1592 ZHENG ET AL. MOL. CELL. BIOL.
that phosphorylation of SLBP may be required for its degra-
dation at the end of S phase (44) (see Fig. 4). We compared the
sequences of the mammalian and Xenopus SLBP1 (42) be-
tween amino acids 57 to 122 (deleted in the 65N mutation) to
identify possible conserved phosphorylation sites (Fig. 2A).
This region is not required for histone pre-mRNA processing
either in vivo (T. C. Ingledue and W. F. Marzluff, unpublished
results) or in vitro (10). Three conserved regions containing
serine or threonine were identified, and the amino acids in
these regions were mutated to alanine (Fig. 2A). Each of these
mutant SLBPs was transfected into HeLa cells, and stable cell
cultures expressing the His-tagged SLBP were generated. These
cultures were synchronized, and the levels of His-tagged and
endogenous SLBP during the cell cycle were analyzed by West-
ern blotting using the anti-SLBP antibody to simultaneously
detect the endogenous and exogenous SLBP. Mutation of ei-
ther the SAVEE region (amino acids 76 to 81) or the patch of
five serines at amino acids 109 to 114 had no effect on the cell
cycle regulation of SLBP (Fig. 2C and D). However, mutation
of the conserved SFTTP sequence at amino acids 58 to 62
resulted in an SLBP which was not degraded at the end of S
phase (Fig. 2B), suggesting that phosphorylation of one or more
amino acids in this region was essential for SLBP degradation.
To further delineate the requirements for SLBP degrada-
tion, we mutated either one or two amino acids in the SFTTP
sequence (Fig. 3A). In addition to mutation of the serines or
threonines, we also mutated proline 62, since many protein
kinases, including the cyclin-dependent kinases, phosphorylate
a TP dipeptide. Each of these mutant proteins was stably
transfected into HeLa cells, the cells were synchronized by a
double-thymidine block, and the SLBP levels were analyzed by
Western blotting. The results for all the mutants are summa-
rized in Table 1.
Mutation of serine 58 to alanine did not affect SLBP stability
(Fig. 3A). However, mutation of both threonine 60 and 61 to
alanine, mutation of either threonine 60 or 61 to alanine, or
mutation of proline 62 to alanine resulted in an SLBP that was
stable at the end of S phase. The amount of these mutant
SLBPs only slowly decreased as cells progressed through G2
and mitosis, while the endogenous SLBP was rapidly degraded
(Fig. 3A). There was no change in the time these cells went
through mitosis as assayed by flow cytometry (Fig. 3B). We
also changed both threonine 60 and 61 to glutamic acid, which
might mimic the phosphorylated protein. This mutant SLBP
was expressed identically to the SFAAP mutant; the protein
was not degraded at the end of S phase. Thus, the substitution
FIG. 2. Amino acids 58 to 62 and 95 to 98 are required for SLBP degradation. (A) The sequences of the N-terminal regions of human (H),
mouse (M), and Xenopus (X) SLBPs are shown (amino acids 55 to 124 in the human and mouse protein). The three conserved possible
phosphorylation sites that were mutated are shown in bold type. The putative cyclin binding site (KRKL) is underlined. Conserved (asterisks) and
similar (dashes) amino acids between two sequences are indicated. (B to E) Plasmids encoding the mutant His-tagged SLBPs (His-SLBPs)
indicated above each panel were stably transfected into HeLa cells, and the cells were synchronized by a double-thymidine block. Protein extracts
were made from the blocked cells (lanes 1) and from cells every 2 h after release from the block (lanes 2 to 7). Equal amounts of protein were
resolved by SDS-polyacrylamide gel electrophoresis, proteins were transferred to nitrocellulose filters, and the endogenous and His-tagged SLBPs
were detected by Western blotting with the anti-SLBP antibody. The time after release and the cell cycle stage is indicated above each lane.
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of two glutamic acids for threonines was not able to mimic the
phosphorylation of the threonines (Table 1; data not shown).
These results strongly implicate phosphorylation of threoni-
nes 60 and/or 61 in SLBP degradation. Since mutation of either
of these residues to alanine had an identical effect on SLBP
stability, it is possible that phosphorylation of both of these
residues is required for the rapid degradation of SLBP at the
end of S phase.
A cyclin recognition motif is required for SLBP degradation.
The requirement for a TP dipeptide and the fact that the
degradation of SLBP is a cell cycle-regulated event suggested
the possible involvement of a cyclin-dependent kinase in SLBP
degradation. Recently, a cyclin binding motif, ZRXL, (where
Z is a Lys or Arg) has been identified in many cyclin binding
proteins (36, 38), including several cyclin/cdk substrates as well
as the p21 class of cdk inhibitors (Table 2). The substrates
include the pRb family, the E2F family, poly(A) polymerase
(4), and a novel cell cycle regulatory protein, HIRA (15).
Inspection of the SLBP sequence reveals a putative cyclin
binding site, KRKL (amino acids 95 to 98 [Fig. 2A]), present in
the region deleted in the 65N mutant (Table 2). We mutated
these amino acids to alanine and stably expressed the mutant
FIG. 3. Threonines 60 and 61 and proline 62 are required for SLBP
degradation. (A) Mutations in the SFTTP sequence are shown at the
left of each blot. The mutant SLBP constructs shown in panel A were
stably transfected into HeLa cells. The cells were synchronized by a
double-thymidine block, and protein extracts were prepared at 2-h
intervals after release from the double-thymidine block. The levels of
SLBP were analyzed by Western blotting using the anti-SLBP antibody
that detects both the endogenous and His-tagged SLBP (His-SLBP).
Lane 1 contains cells blocked at the G1/S border, and lanes 2 to 7
contain cells after release from the block. The time after release is
indicated above each lane. (B) Flow cytometry analysis of the cells
transfected with the T60/T61 mutant of SLBP. Chromosome content is
shown on the x axis, and cell number is shown on the y axis.
TABLE 1. Cell cycle expression of mutant SLBPsa
















a Pools of stable cells that express the indicated SLBPs tagged with either HA
(the deletion mutants) or His (the site-specific mutations) were synchronized by
a double-thymidine block. The levels of the mutant and endogenous SLBP levels
were measured by Western blotting using the antibody against SLBP. A regu-
lated mutant is degraded in parallel with the endogenous SLBP, and a stable
mutant is degraded slowly only at the end of S phase.





















a The cyclin binding sites from cdk inhibitors (p21, p27, and p57) and cdk
substrates are shown and compared with the sequence in SLBP (amino acids 95
to 100).
b The N-terminal (N) and C-terminal (C) regions of p21 are shown.
c HPV, human papillomavirus.
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protein in HeLa cells. Mutation of these four amino acids
resulted in an SLBP that was stable as cells exited S phase (Fig.
2E), i.e., that behaved identically to the mutants in the SFTTP
sequence. This result suggests that phosphorylation of SLBP by
a member of the cyclin/cdk family is required for degradation
of SLBP at the end of S phase.
Phosphorylation of SLBP at the end of S phase. A phos-
phorylated form of SLBP accumulates in cells treated with
MG132 near the end of S phase (44). In control cells, there is
a small amount of phosphorylated SLBP, identified by its re-
duced electrophoretic mobility (44), and the phosphorylated
SLBP is present exclusively in the cytoplasm (Fig. 4A, lanes 1
and 2). In the late S-phase cells treated with MG132, there is
an increase in the amount of the phosphorylated form of
SLBP, and all of the phosphorylated SLBP is present in the
cytoplasm (Fig. 4A, lanes 3 and 4). To determine whether the
phosphorylated SLBP that accumulates in these cells is capable
of binding to the stem-loop, we incubated the extract with a
biotinylated RNA, isolated the RNA with streptavidin agarose,
and then analyzed the beads for the presence of SLBP (Fig.
4A, lanes 5 and 6). The phosphorylated form of SLBP was
selected as efficiently as the unphosphorylated form of SLBP
(more than 85% of each was bound to the beads), and neither
form bound to a biotinylated RNA with the stem sequence
reversed (Fig. 4A, lane 7).
To explicitly determine whether SLBP is phosphorylated on
the SFTTP sequence at the end of S phase, we used MS to
detect the phosphorylated peptide. Since the phosphorylated
protein accumulates only in cells treated with MG132 near the
end of S phase (unpublished results), we synchronized large
amounts of cells, treated them with MG132 for 4 h to accu-
mulate phosphorylated SLBP, and then purified the His-
tagged phosphorylated protein for analysis by MS. We could
not routinely detect phosphorylated forms of the His-tagged
SLBPs by changes in electrophoretic mobility, presumably an
effect of the epitope tag on electrophoretic behavior of the
protein. We analyzed two samples, one expressing the wild-
type protein and the other expressing the SLBPKRKL-AAAA,
which has the cyclin binding motif mutated. Each of these
proteins contains the same sequence in the tryptic peptide that
contains the SFTTP sequence. For standards, we synthesized
peptides that contained the SFTTP sequence with both
threonines or one threonine (T61) phosphorylated. The His-
tagged SLBP was purified in two steps. The whole-cell extract
was passed over Ni-agarose to enrich for the His-tagged SLBP
and remove the endogenous SLBP (Fig. 4B, lanes 2 and 3).
The bound fraction which contained the His-tagged SLBP plus
other proteins (Fig. 4C, lane 1) was incubated with a biotinyl-
ated stem-loop to isolate the proteins that bind specifically to
this RNA. An aliquot of the proteins was analyzed by gel
electrophoresis. After the two fractionation steps, the major
protein remaining is the His-tagged SLBP as detected by stain-
ing with Coomassie blue (Fig. 4C, lane 2).
The remainder of the sample was then digested with trypsin
and analyzed by capillary LC-MS/MS. This technique was used
to determine the relative amounts of the mono- and diphos-
FIG. 4. Purification of His-tagged SLBP. (A) HeLa cells were synchronized by a double-thymidine block and released for 4 h, and then MG132
was added for an additional 4 h. Cells were fractionated into nuclear and cytoplasmic fractions, and samples from equal amounts of cells were
resolved by gel electrophoresis, and SLBP was detected by Western blotting. Lanes 1 and 2 contain cells harvested 4 h after release from the
thymidine block (control). Lanes 3 and 4 contain cells harvested after treatment with MG132 for 6 h, starting 4 h after release. The cytoplasmic
lysate from cells treated with MG132 for 6 h (lane 5) was incubated with a biotinylated wild-type (WT) stem-loop RNA (lane 6) or a biotinylated
mutant stem-loop RNA with the stem sequence reversed (RS) (lane 7) and then the RNA bound to streptavidin beads. An equivalent amount of
total lysate and protein bound to the beads was analyzed by gel electrophoresis, and the SLBP was detected by Western blotting. (B) Cells
expressing the His-tagged SLBP (His-SLBP) were synchronized by a double-thymidine block. Four hours after release from the block, MG132 was
added for 4 h. Total cell extract was fractionated on Ni-agarose, and the bound proteins were eluted with imidazole. Aliquots of the total lysate
(0.1% [lane 1]), unbound protein (0.1% [lane 2]), and bound protein (1% [lane 3]) were analyzed by gel electrophoresis, and the SLBP was
detected by Western blotting. The position of the 51-kDa molecular mass marker is indicated to the right of the blot. (C) A biotinylated stem-loop
RNA was incubated with the proteins eluted from Ni-agarose, and then streptavidin agarose was added. The resin was washed extensively, and an
aliquot of the beads analyzed by SDS-polyacrylamide gel electrophoresis (5% of the total [lane 2]) together with an aliquot of the proteins bound
to Ni-agarose (1% of the total [lane 1]). The proteins were detected by staining with Coomassie blue. Note that the His-tagged SLBP (His-SLBP)
is not detectable by staining of the total proteins bound to Ni-agarose. The positions of molecular mass markers (in kilodaltons) (lane 3) are shown
to the left of the gel.
VOL. 23, 2003 CELL CYCLE REGULATION OF SLBP 1595
phorylated peptide found in wild-type versus mutant His-
tagged SLBP. The same amount of wild-type and mutant pro-
tein was injected. The extracted ion chromatograms show that
there was only a trace of the monophosphorylated peptide in
the wild-type sample (Fig. 5A, left panel), while this peptide
was very abundant in the His-tagged SLBP with the mutation
of the cyclin binding site (Fig. 5A, right panel). Figure 5B
shows the product ion spectrum acquired while this component
was eluting. This MS/MS spectrum shows that the phosphoryl
group is on S58 or T60, but not on T61, consistent with the
phosphorylation of T61 being due to a cyclin/cdk.
When we analyzed for the presence of the diphosphorylated
peptide in the same samples, we detected the diphosphorylated
peptide in the wild-type His-tagged protein (Fig. 5C) and did
not detect any diphosphorylated peptide in the cyclin binding
site mutant proteins (not shown). The sensitivity of detection
for the diphosphorylated peptide was 10- to 20-fold lower than
the monophosphorylated peptide using the synthetic peptides
as standards, accounting for the relatively low signal to noise.
Fragmentation analysis of the peptide was consistent with its
assignment as the diphosphorylated peptide (Fig. 5D) and
identical to that observed with the synthetic standard. Thus, in
late S-phase cells treated with MG132, SLBP phosphorylated
on both T60 and T61 accumulates, consistent with this being
the signal for degradation. In the stable mutant SLBP, which
has the cyclin binding site mutated, only T60 is phosphorylated,
which is not sufficient to cause SLBP degradation.
Stabilization of SLBP does not affect histone mRNA degra-
dation at the end of S phase. After histone pre-mRNA pro-
cessing, SLBP accompanies the mRNA to the cytoplasm and is
associated with the histone mRNA on polyribosomes (9, 16).
Recombinant SLBPs with mutations or deletions in the amino
terminus are fully active in processing in vitro (10), suggesting
that they should substitute for the endogenous SLBP in histone
mRNPs. To determine whether the T61A SLBP mutant that is
stable at the end of S phase is associated with histone mRNAs
in vivo, we fractionated S-phase cells into nuclear and poly-
ribosomal fractions and analyzed each fraction for the two
SLBPs. The ratio of the His-tagged SLBP to the endogenous
SLBP was the same in each cell fraction (Fig. 6A), suggesting
that it efficiently substitutes for the endogenous SLBP and
was associated with histone mRNA on polyribosomes in S
phase (Fig. 6A, lane 2). Identical results were obtained with
the wild-type His-tagged SLBP (not shown) and the T60A/
T61A SLBP.
At the end of S phase, the histone mRNA is rapidly de-
graded at about the same time that SLBP is normally degraded
(44), raising the possibility that the degradation of SLBP and
histone mRNA are coupled. We determined whether histone
mRNA metabolism was regulated normally in cells expressing
the stable SLBP. Histone mRNA was degraded at the end of S
phase in cells expressing both the S58A SLBP, which was
degraded like the wild-type SLBP (Fig. 6B, lanes 4 to 7), and
the T60A/T61A SLBP, which is stable (Fig. 6C, lanes 4 to 7).
Thus, degradation of SLBP is not required for degradation
of histone mRNA at the end of S phase. Similar results have
been found for cells treated with inhibitors of DNA repli-
cation in S phase; histone mRNA is rapidly degraded while
SLBP is stable (M. L. Whitfield and W. F. Marzluff, unpub-
lished results).
SLBP is the only limiting factor for histone pre-mRNA pro-
cessing in continuously cycling cells. Histone pre-mRNA pro-
cessing is activated as cells progress from G1 to S phase (17)
and is likely also down-regulated at the end of S phase. The
changes in SLBP levels that occur during the cell cycle might
be solely responsible for this regulation. Since there are other
factors required for histone pre-mRNA processing, it is also
possible that additional factors are also regulated during the
cell cycle. To determine whether SLBP is the major factor
responsible for regulation of histone pre-mRNA processing,
we prepared nuclear extracts from S-, G2-, and G1-phase cells
after release of cells from the double-thymidine block. The
degree of synchrony of these cultures was determined by flu-
orescence-activated cell sorter analysis (Fig. 7C). Western blot
analysis demonstrated that there were significant amounts of
SLBP present only in the S-phase cells and that as expected
SLBP was located primarily in the nucleus and on the polyri-
bosomes (Fig. 7A). Each nuclear extract was tested for the
ability to process histone pre-mRNA and the ability of recom-
binant SLBP to stimulate histone pre-mRNA processing. Ex-
tracts prepared from S-phase cells (2 h after release from
the double-thymidine block) processed histone H2a-614 pre-
mRNA, and addition of recombinant SLBP increased the in
vitro processing activity only about 50% (Fig. 7B, lanes 1 and
2). In contrast, extracts prepared from both G2- and G1-phase
cells (8 and 14 h after release from the double-thymidine block,
respectively) had very little processing activity (Fig. 7B, lanes 3
and 5). Addition of recombinant SLBP to either of these ex-
tracts resulted in a fivefold stimulation of the efficiency of
processing, increasing the processing activity to close to the
level of the S-phase extracts (Fig. 7B, lanes 4 and 6).
We also tested the processing activity in extracts from G2-
phase cells expressing a stable SLBP. Cells expressing the
T60A mutation were synchronized, and nuclear and cytoplas-
mic extracts were prepared from S-phase cells. Western blot-
ting confirmed that the endogenous SLBP had been degraded
in the G2-phase cells, which contained only the mutant SLBP
(Fig. 8A). The mutant SLBP was present in both the nuclear
and cytoplasmic fractions. In agreement with the results in Fig.
6A, the mutant and wild-type proteins were distributed simi-
larly in the S-phase cells. In the G2-phase cells, there was a
higher fraction of the protein in the cytoplasm than in the
S-phase cells (Fig. 8A). The extracts from G2 cells were tested
for SLBP binding activity using a mobility shift assay. There
was reduced activity in the G2-phase extract compared with the
S-phase extract (Fig. 8B) cells, in agreement with the lower
amount of SLBP protein in the G2-phase nuclear extract (both
because the wild-type protein has been degraded and because
a larger fraction of the mutant protein is in the cytoplasm). We
tested the S-phase and G2-phase extracts from cells expressing
the T60A mutant for their ability to process histone pre-
mRNA and for the ability of SLBP to stimulate processing.
Both these extracts process histone pre-mRNA. The S-phase
extract was slightly more efficient than the G2-phase extract,
likely because of the reduced amount of SLBP in the G2-phase
extract. However, the G2-phase extract was significantly more
active than the G2-phase extract from wild-type cells (Fig. 7B,
lane 3). Addition of recombinant SLBP had little effect on the
activity of the S-phase extract and stimulated activity of the G2
extract about twofold, bringing it up to the level of the S-phase
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extract. Thus, the stable T60A SLBP in the G2-phase extract
was functional in histone pre-mRNA processing. These results
demonstrate that SLBP is the sole cell cycle-regulated factor
required for histone pre-mRNA processing in vitro.
DISCUSSION
Phosphorylation of SLBP on T60 and T61 is required for
SLBP degradation. The levels of SLBP are regulated during
the cell cycle. SLBP is up-regulated by a translational mecha-
nism at the G1/S transition and is degraded at the end of S
phase (17, 44). Treatment of cells in late S phase with the
proteasome inhibitor MG132 prevents SLBP degradation at
the end of S phase and results in the accumulation of a phos-
phorylated form of SLBP, suggesting that phosphorylation of
SLBP may be the trigger for its degradation (44). Using a
series of deletion mutants followed by site-directed mutation
analysis, we found that mutation of either T60 or T61 to ala-
nine stabilizes SLBP. T61 is immediately followed by a proline
that is also essential for SLBP degradation, and hence SLBP is
a possible substrate for a cyclin-dependent kinase. In support
of this possibility, we found a potential cyclin binding site
located 35 amino acids from the putative cyclin/cdk phosphor-
ylation site. Mutation of this site to alanines also resulted in
stabilization of SLBP at the end of S phase.
The degradation of several proteins is regulated during tran-
sitions from one phase of the cell cycle to the next. Two major
complexes responsible for ubiquitination and subsequent deg-
FIG. 5. LC-MS/MS analysis of His-tagged SLBP phosphorylation. (A) The purified His-tagged SLBP (Fig. 4C, lane 2) was digested with trypsin
and subjected to mass spectrometric analysis. Wild-type SLBP (left) and the KRKL mutant SLBP (right) are shown. Extracted ion chromatograms
of the product ion at m/z 527.6, which corresponds to the loss of a mass increment of 32.67 or H3PO4 from the triple-charged monophosphorylated
peptide T13 of His-tagged SLBP at m/z 560.27. (B) LC-MS/MS spectrum of the tryptic peptide T13 from the His-tagged KRKL mutant SLBP,
containing the SFTTP sequence, showing that the phosphoryl group is on either S58 or T60, but not T61. (C) Extracted ion chromatogram of the
product ion at m/z 521.63 corresponding to the loss of 65.34 (two HPO3) from the triple-charged diphosphorylated SLBP peptide T13 (m/z 592.94)
from the wild-type sample. (D) LC-MS/MS spectrum from the precursor ion at m/z 592.94 obtained at 70.65 min (panel C), confirming the presence
of the diphosphorylation of the SLBP peptide T13 in the wild-type sample. The achieved fragment ions together with the MS/MS analysis from
a synthetic SLBP T13 peptide phosphorylated at the equivalent position as T60 and T61 (data not shown) demonstrate that both threonine residues
in the wild-type sample are phosphorylated. amu, atomic mass unit.
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radation of proteins during the cell cycle have been identified:
the anaphase-promoting complex (APC)/cyclosome and the
SCF complex. The APC is activated in mitosis (30) and re-
mains active through the next G1 phase (5). The APC recog-
nizes a specific amino acid sequence, termed the destruction
box, which is present in most proteins targeted for degradation
by the APC. Since SLBP is degraded at the end of S phase or
early G2 phase, it is unlikely that the APC is involved in the
degradation of SLBP. The SCF complexes, a prototype of the
Cullin/Roc1/2 complexes, are active throughout the cell cycle
and are involved in degradation of specific proteins at the G1/S
transition. They are responsible for the ubiquitination of S-
phase inhibitors, Sic1 (12) and p27 (33), and the G1 cyclin,
cyclin E (22, 29, 41). SCFs are also involved in protein degra-
dation at the G2/M transition, for example for the degradation
of the Wee1 kinase (28). The specificity of the SCF is provided
by F-box proteins, which recognize the specific substrates.
Since the F-box proteins recognize only phosphorylated sub-
strates, synthesis of the F-box protein and/or phosphorylation
of the substrate may be the regulatory step that triggers ubiq-
uitination by SCF complexes.
FIG. 6. Histone mRNA is degraded in the presence of a stable
SLBP. (A) Cells transfected with the T61A SLBP were synchronized
by a double-thymidine block, and the cells were harvested in S phase
(4 h after release) and fractionated into nuclear (N) and polyribosomal
(P) fractions. The amount of SLBP in each fraction was analyzed by
Western blotting using the anti-SLBP antibody to detect both the
His-tagged SLBP (His-SLBP) and endogenous SLBP. (B and C) HeLa
cells transfected with the S58A mutant SLBP (B) and the T60A/T61A
SLBP (C) were synchronized by a double-thymidine block. RNA was
prepared from the blocked cells (lanes 1) and from cells at 2-h intervals
after release from the block (lanes 2 to 7). Ten micrograms of total cell
RNA was resolved by gel electrophoresis, transferred to a Nytran mem-
brane, and probed with either the histone H3 gene (top panel) or the
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA. The
time after release and the cell cycle stage is indicated above each lane.
FIG. 7. SLBP is the only essential histone pre-mRNA processing
factor missing from G1 and G2 nuclear extracts. (A) HeLa cells were
synchronized by a double-thymidine block, and equal cell equivalents
of nuclear, polyribosomal, and cytosol fractions were prepared from S
phase (3 h after release [lanes 2, 5, and 8]), G2 phase (8.5 h after re-
lease [lanes 3, 6, and 9]) and G1 phase (14 h after release [lanes 1, 4,
and 7]) and analyzed for SLBP by Western blotting. (B) The nuclear
extracts prepared from S-, G2-, and G1-phase cells were analyzed for
processing activity using the H2a-614 pre-mRNA as a substrate. Re-
combinant SLBP was added to the extracts in lanes 2, 4, and 6 prior to
addition of the pre-mRNA substrate. RNA was prepared from the
reaction mixtures, and the pre-mRNA (Unproc) and processed mRNA
(Proc) were resolved by gel electrophoresis. The results are represen-
tative of three independent preparations of synchronous cells. (C)
Flow cytometric analysis of the cells used for preparation of the S-
phase (3 h), G2-phase (8.5 h), and G1-phase (14 h) extracts, respec-
tively. Chromosome content is shown on the x axis, and cell number is
shown on the y axis.
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The phosphorylation of both threonines 60 and 61 are re-
quired for SLBP degradation at the S/G2 border. We also
identified a putative cyclin binding site, and mutation of the
cyclin recognition motif, KRKL, stabilizes SLBP, providing
additional evidence that phosphorylation of SLBP by a cyclin-
cdk is required for SLBP degradation. SLBP containing this
mutation is still phosphorylated at T60 (Fig. 5B), demonstrat-
ing that this phosphorylation at T60 either precedes the cyclin/
cdk phosphorylation of T61 or can occur independently of this
phosphorylation. We detected phosphorylation of both T60
and T61 in wild-type SLBP in late S-phase cells when the
proteasome was inhibited (Fig. 5C). Since mutation of the
SAVEE and SSSGSS sequences, which flank the cyclin binding
site, does not affect SLBP degradation, it is unlikely that the
mutation of KRKL affects SLBP degradation by disrupting its
conformation. These results strongly argue that phosphoryla-
tion of threonines 60 and 61 is essential for SLBP degradation.
Since the phosphorylation of SLBP is essential for its degra-
dation, it is possible that SLBP is also a substrate of the SCF,
with a specific F-box protein required for its degradation.
Since SLBP is degraded at the end of S phase or early G2
phase and cyclin B/cdc2 is activated at the beginning of mitosis,
it is unlikely that phosphorylation of SLBP by cyclin B/cdc2
could play any role in SLBP degradation. A candidate cyclin-
cdk that is active in late S phase is cyclin A/cdk2. The identity
of the second kinase that phosphorylates T60 is not known. It
is likely that these two threonines are phosphorylated indepen-
dently (the phosphorylation of one site does not require pre-
vious phosphorylation of the other site), since the KRKL mu-
tation blocks the phosphorylation of T61 but not T60. There
are no precedents of phosphorylation of cdk sites requiring a
neighboring phosphorylation. In preparations of recombinant
SLBP expressed in baculovirus, some of the SLBP is phosphor-
ylated on T61 and not T60 (our unpublished results with J. A.
Erkmann), which is consistent with these phosphorylations be-
ing independent.
Preventing degradation of SLBP does not result in deregu-
lation of histone mRNA. All of the stably transfected SLBPs
were expressed at similar levels to the endogenous SLBP, re-
sulting in no more than two- to threefold-higher expression of
total SLBP levels in the stably transfected cells in S phase. The
His-tagged SLBPs function in histone pre-mRNA processing
in vitro (10) and associate with the histone mRNP in vivo, as
judged by association of the tagged SLBP with polyribosomes.
The presence of stable SLBP at the end of S phase does not
prevent the degradation of histone mRNA. This is consistent
with our observation that SLBP is not degraded when cells are
treated with inhibitors of DNA replication, although histone
mRNA is rapidly degraded (M. L. Whitfield and W. F. Marz-
luff, unpublished results).
SLBP is the only regulated factor required for histone pre-
mRNA processing. Nuclear extracts prepared from exponen-
tially growing cells are capable of processing synthetic histone
pre-mRNAs in vitro. Processing requires that SLBP binds to
the histone pre-mRNA. U7 snRNP then binds to the histone
downstream element and its binding is stabilized by SLBP (8).
There are likely other factors required for histone pre-mRNA
processing that have not been well characterized (8, 10, 14). In
vivo, histone pre-mRNA processing is regulated, both in cells
arrested in G0/G1 (23, 40) and in continuously cycling cells
(17). Since SLBP is required for efficient histone pre-mRNA
processing, extracts prepared from G1- and G2-phase cells,
which contain little SLBP, were essentially inactive in histone
pre-mRNA processing. Addition of exogenous SLBP restored
the processing activity of G1- and G2-phase nuclear extracts to
levels similar to those in S-phase nuclear extracts, suggesting
that SLBP is the only limiting factor for histone mRNA pro-
cessing in both G2 and G1 phase. The SLBP that is stable
remains active in histone pre-mRNA processing, since nuclear
extracts prepared from cells in G2 phase expressing the T60/
T61 stable mutant of SLBP are active in histone pre-mRNA
processing (Fig. 8). Taken together, this evidence strongly sug-
gests that SLBP is the sole essential cell cycle-regulated factor
for histone pre-mRNA processing.
Two other possible mechanisms for the posttranscriptional
regulation of histone pre-mRNA processing have been pro-
posed: cell cycle regulation of a heat-labile factor (14, 23) or
the cell cycle-regulated accessibility of the 5 end of U7 snRNA
(20). Our results demonstrate that the U7 snRNP present in
the G1- or G2-phase extracts is active in processing. Indeed,
there is a basal level of processing of the H2a-614 pre-mRNA
in G2- and G1-phase nuclear extracts which is dependent on
U7 snRNP and independent of SLBP (9, 10). If there is a
heat-labile factor that is regulated in cells arrested in G0/G1, it
FIG. 8. G2 extracts from cells expressing a stable SLBP are active in
histone pre-mRNA processing. Cells stably expressing the T60A mu-
tant SLBP were synchronized, and nuclear extracts and cytoplasm were
prepared from S- and G2-phase cells. Equal amounts of protein were
used in the assays for SLBP activity below. (A) Ten micrograms of
nuclear (N) and cytoplasmic (C) proteins from S-phase (lanes 1 and 2)
or G2-phase (lanes 3 and 4) cells were resolved by electrophoresis on
an SDS–8% polyacrylamide gel, and SLBP was detected by Western
blotting using antibody against the C-terminal peptide of SLBP. Note
that the cytoplasm had 10 times more protein than the nuclear extract,
so only 10% as many cell equivalents were analyzed in lanes 2 and 4.
His-SLBP, His-tagged SLBP. (B) Equal amounts of nuclear extract
from S-phase and G2-phase cells was incubated with a radiolabeled
stem-loop (SL) (lane 1), and the complexes were resolved by native gel
electrophoresis. (C) Equal amounts of S-phase (lanes 1 and 2) and
G2-phase (lanes 3 and 4) cells were incubated with radiolabeled his-
tone pre-mRNA, and the RNA products were analyzed by gel elec-
trophoresis and detected by autoradiography. In lanes 2 and 4, recom-
binant SLBP was added to the extracts prior to addition of the
substrate. The positions of pre-mRNA (Unproc) and processed
mRNA (Proc) are shown to the right of the gel.
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is not regulated in continuously cycling cells. Many proteins
necessary for cell cycle progression are down-regulated in cells
arrested in G0/G1 but are not regulated in continuously cycling
cells, since the proteins are relatively stable.
Additional events regulating histone mRNA accumulation.
Histone mRNAs are not present in G2 cells expressing a stable
SLBP. Histone mRNAs are also not present in cells arrested at
the G1/S border, even though these cells contain large amounts
of SLBP, and extracts from these cells are active in histone pre-
mRNA processing (unpublished results). One likely reason for
the failure of histone mRNA to accumulate in these cells is
that the mRNA is very unstable in the cytoplasm when there is
not ongoing DNA replication. However, it is possible that
there are also nuclear events that are regulated that result in
histone mRNA being processed in the nucleus and degraded
without being exported to the cytoplasm. If such a regulatory
system exists and is cell cycle regulated, it could help ensure
the rapid accumulation of histone mRNA as cells enter S phase
and the cessation of production of cytoplasmic histone mRNA
at the end of S phase.
Cell cycle signals regulate SLBP levels. Histone mRNAs and
SLBP are both expressed at high levels only in S-phase cells.
Since SLBP remains with the histone mRNA after histone pre-
mRNA processing, SLBP is stoichiometrically required for ac-
cumulation of histone mRNA. However, histone mRNAs and
SLBP are not regulated by the same signals and mechanisms.
We previously observed that SLBP is present in cells blocked
at the G1/S border, suggesting that SLBP starts to accumulate
in late G1, prior to the accumulation of histone mRNA (44).
Similarly, when S-phase cells are treated with inhibitors of
DNA replication, histone mRNAs are degraded while SLBP is
stable (unpublished results with M. L. Whitfield). Thus, all the
evidence is consistent with histone mRNAs being regulated in
response to changes in the rate of DNA synthesis, while SLBP
is regulated by cell cycle signals. This suggests that the degra-
dation of SLBP at the end of S phase inhibits histone pre-
mRNA processing and functions to prevent further accumula-
tion of histone mRNA prior to entry into the next cell cycle.
Only when cells resynthesize SLBP as they approach S phase
can they then accumulate histone mRNA.
There is no obvious phenotype in HeLa cells of persistent
expression of SLBP through G2. Histone mRNA is degraded at
the normal time with normal kinetics in these cells, so there
will not be continued production of histone proteins during G2.
Since the half-life of SLBP in S-phase cells is about 2 h and
since the synthesis of SLBP is reduced at the end of S phase (L.
Zheng, unpublished results) and during G1, due to regulation
of translation of SLBP mRNA (44), there are not high levels of
the stable SLBP throughout G1 in the cells expressing the
stable SLBP. It is possible that the presence of the stable SLBP
will result in precocious expression of some histone mRNA in
G1 phase. However, in addition to the control of SLBP deg-
radation, a higher percentage of the stable SLBP accumulates
in the cytoplasm (Fig. 8B). This may be a secondary mecha-
nism for stopping histone mRNA biosynthesis at the end of S
phase.
The limitation of histone mRNA accumulation to S phase is
likely to be important for proper chromatin function during
development, although it may be less critical in a transformed
cultured cell. It is becoming increasingly clear that there is a
high level of specificity for assembly of variant core histones
into nucleosomes, much of which may occur outside of S phase
(for example, the H3cid protein, H3.3 protein, and H2a.X and
H2a.Z proteins). These variants have specific functions (1, 2,
11, 19, 21, 34, 35). If large amounts of core histones are pro-
duced outside of S phase, then they could compete for special-
ized histone variants disrupting appropriate chromatin struc-
ture (26).
Exit from G1 and exit from mitosis both require degradation
of specific critical proteins. Although SLBP degradation is not
essential for the progression of the cell cycle, it is likely that
there may be a group of proteins coordinately targeted for
degradation as cells exit S phase and enter G2 phase and that
some of these proteins are essential for cell cycle progression.
Study of SLBP degradation will likely lead to further under-
standing of other proteins that are degraded at the end of S
phase.
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